Synairgen (SYNG)

London
148.80
-5.80(-3.75%)
  • Volume:
    423,401
  • Bid/Ask:
    149.20/149.80
  • Day's Range:
    148.80 - 154.87

SYNG Overview

Prev. Close
154.6
Day's Range
148.8 - 154.87
Revenue
0
Open
148.91
52 wk Range
32.52 - 258.46
EPS
-0.05
Volume
423,401
Market Cap
299.21M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,892,488
P/E Ratio
N/A
Beta
-7.42
1-Year Change
154.95%
Shares Outstanding
199,914,402
Next Earnings Date
May 24, 2021
What is your sentiment on Synairgen?
or
Vote to see community's results!

Synairgen News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellStrong SellBuy
Technical IndicatorsSellSellNeutralStrong SellBuy
SummaryStrong SellSellSellStrong SellBuy

Synairgen Company Profile

Synairgen Company Profile

Employees
14

Synairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Read More
  • looks like some good news may be coming...
    1
    • Graham, a lot of SYNG's work is in trial phases and there tends to be not much movement then an increase when a trial is underway. I hope that we will see more significant moves upwards once trials prove successful. It looks like its going in the right direction so I'm holding for now.
      1
      • Thanks for response, i knew pretty much what you've said there phase 3 seems very interesting with aniti viral inhaler, im holding long term.
        0
    • Anyone's thoughts on this seen it mentioned repeatedly yet not taken off, also huge development into antiviral drugs!
      1
      • Lansdowne is a distressed seller that has been selling down aggressively since the 24th Aug, but if you can see past the short term drag on the share price, this company is only going one way: up up and to a partnership with a big pharma. Target of £1-4bn mcap
        1
        • They're going to be adopted by UK health system and many others for a patent that has been showed in peer reviewed research to deflect the need of reanimation therapies in COVID affected patients... great buy...
          0
          • buy?
            2
            • What happen to this stock ?
              0
              • will this continue tomorrow??
                0
                • AstraZeneca pozitiv news!
                  0
                  • bet woodford is feeling ill and / or justified. He was a big shareholder.
                    0
                    • game changer
                      0
                      • 240 WOW
                        0
                        • Has the drug been confirmed about its effectiveness?
                          0
                          • Wow....
                            0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.